welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

Pfizer Rival Breaks Out After Obliterating Sales Expectations

Investor's Business Daily
Summary
Nutrition label

85% Informative

BridgeBio 's drug, Attruby , treats transthyretin amyloid cardiomyopathy, a condition in which abnormal protein builds up on the heart.

Pfizer 's rival drug, Vyndaqel , generated $1.49 billion in first-quarter sales.

VR Score

89

Informative language

94

Neutral language

4

Article tone

formal

Language

English

Language complexity

52

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links